Gerben van’t Klooster

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Florence Namour, Paul M. Diderichsen, Eugène Cox et al. · Clinical Pharmacokinetics · 2015 · 136 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions

Florence Namour, Julie Desrivot, Annegret Van der Aa et al. · Drug Metabolism Letters · 2016 · 56 citations

Medicine, Pharmacokinetics, Pharmacology +17

Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects

Florence Namour, René Galien, Tim Van Kaem et al. · British Journal of Clinical Pharmacology · 2016 · 55 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen

Sanjay UC Sankatsing, Gerrit Jan Weverling, Monika Peeters et al. · AIDS · 2003 · 38 citations

Medicine, Pharmacology, Pharmacotherapy +17

11 OPERA-1 TRIAL: INTERIM ANALYSIS OF SAFETY AND ANTIVIRAL ACTIVITY OF TMC435 IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS

M.P. Manns, H.W. Reesink, Christophe Moreno et al. · Journal of Hepatology · 2009 · 25 citations

Medicine, Infectious Diseases, Pharmacology +13